Moderna Inc (NASDAQ:MRNA)’s traded shares stood at 5.61 million during the last session, with the company’s beta value hitting 2.18. At the close of trading, the stock’s price was $32.45, to imply a decrease of -2.61% or -$0.87 in intraday trading. The MRNA share’s 52-week high remains $170.47, putting it -425.33% down since that peak but still an impressive 9.86% since price per share fell to its 52-week low of $29.25. The company has a valuation of $12.52B, with an average of 9.07 million shares in intraday trading volume over the past 10 days and average of 11.72 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Moderna Inc (MRNA), translating to a mean rating of 2.89. Of 17 analyst(s) looking at the stock, 2 analyst(s) give MRNA a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 12 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -3.14.
Moderna Inc (NASDAQ:MRNA) trade information
After registering a -2.61% downside in the last session, Moderna Inc (MRNA) has traded red over the past five days. The 5-day price performance for the stock is -5.39%, and -9.61% over 30 days. With these gigs, the year-to-date price performance is -21.96%. Short interest in Moderna Inc (NASDAQ:MRNA) saw shorts transact 45.06 million shares and set a 3.6 days time to cover.
The extremes give us $45 and $69 for target low and target high price respectively. As such, MRNA has been trading -112.63% off suggested target high and -38.67% from its likely low.
Moderna Inc (MRNA) estimates and forecasts
The rating firms project that company’s revenue will shrink -32.93% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 134.65M. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 121.23M.Earnings reports from the last fiscal year show that sales brought in 167M and 241M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -19.37% before dropping -49.70% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -42.94% for the past 5-year period. While 2025 is set for a -8.81% return in earnings, projections for the next 5 years are at 14.68% annually.
MRNA Dividends
Moderna Inc has its next earnings report out on 2025-Feb-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Moderna Inc (NASDAQ:MRNA)’s Major holders
Moderna Inc insiders hold 7.27% of total outstanding shares, with institutional holders owning 72.77% of the shares at 78.47% float percentage. In total, 72.77% institutions holds shares in the company, led by BAILLIE GIFFORD & CO. As of 2024-06-30, the company held over 43.45 million shares (or 11.3149% of shares), all amounting to roughly $5.16 billion.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 39.56 million shares, or about 10.3568% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $4.7 billion.
We also have Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund as the top two Mutual Funds with the largest holdings of the Moderna Inc (MRNA) shares. Going by data provided on Dec 31, 2024 , Vanguard Total Stock Market Index Fund holds roughly 10.87 shares. This is just over 2.82% of the total shares, with a market valuation of $352.7 million. Data from the same date shows that the other fund manager holds a little less at 9.17, or 2.38% of the shares, all valued at about 297.41 million.
